Therapy and clinical trials in frontotemporal dementia: past, present, and future
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Frontotemporal dementia (FTD) is a common form of dementia with heterogeneous clinical presentations and distinct clinical syndromes. This article will review currently available therapies for FTD, its related disorders and their clinical evidence. It will also discuss recent advancements in FTD pathophysiology, treatment development, biomarker advancement and their relation to recently completed or currently ongoing clinical trials as well as future implications. image Frontotemporal dementia (FTD) is a type of dementia with distinct clinical syndromes. Current treatments involve off‐label use of medications for symptomatic management and cannot modify disease course. Advancements in FTD pathophysiology, genetics, and biomarkers have led to development of small molecules targeting the underlying pathology in hopes of achieving a disease‐modifying effect. This article will review current therapies for FTD, discuss advancements in FTD pathophysiology, therapy development, biomarker advancement, their relation to recent clinical trials and future implications. This article is part of the Frontotemporal Dementia special issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936 · cited 2×
“In 2011, a hexanucleotide repeat expansion in the 5 0 non-coding region of the C9ORF72 gene was found to be the cause of FTD and ALS in a strongly chromosome 9p linked family (Boxer et al. 2011; DeJesus-Hernandez et al. 2011; Renton et al. 2011).”
Self-citationA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409 · cited 1×
“In 2011, a hexanucleotide repeat expansion in the 5 0 non-coding region of the C9ORF72 gene was found to be the cause of FTD and ALS in a strongly chromosome 9p linked family (Boxer et al. 2011; DeJesus-Hernandez et al. 2011; Renton et al. 2011).”
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Self-citationTau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949
RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention
Donnelly, C. J., Zhang, P.-W., Pham, J. T., Haeusler, A. R., Mistry, N. A., Vidensky, S., Daley, E. L., Poth, E. M., Hoover, B., Fines, D. M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.015 · Cited by 877
Tang, W., Lu, Y., Tian, Q.-Y., Zhang, Y., Guo, F.-J., Liu, G.-Y., Syed, N. M., Lai, Y., Lin, E. A., Kong, L., et al. (2011) · Science · doi:10.1126/science.1199214 · Cited by 761
Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K. M. G., Grant, S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L., Sahabian, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007529 · Cited by 670 · cited 2×
“Several ASO candidates are in pre-clinical development and demonstrated reduction in RNA aggregation without toxic effects in human C9ORF72 induced pluripotent stem cell neuron and fibroblast (Donnelly et al. 2013; Lagier-Tourenne et al. 2013; Sareen et al. 2013).”
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617 · cited 2×
“In addition, it has been demonstrated that patients with GRN mutation often have co-existing autoimmune disorders (Miller et al. 2013a).”
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · cited 2×
“Over the past 4 years, multiple studies have demonstrated that injection of anti-tau antibodies to various tau epitopes in tau transgenic mouse models resulted in reduction in tau pathology, with three studies reporting cognitive or functional improvement (Boutajangout et al. 2011; Chai et al. 2011; d’Abramo et al. 20…”
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547
Snowden, J. S., Rollinson, S., Thompson, J. C., Harris, J. M., Stopford, C. L., Richardson, A. M. T., Jones, M., Gerhard, A., Davidson, Y. S., Robinson, A., et al. (2012) · Brain · doi:10.1093/brain/awr355 · Cited by 523
Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits
Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, S. S., Defensor, E., Mok, S. A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3951 · Cited by 516 · cited 1×
“Recently a non-steroidal anti-in fl ammatory drug salsalate was found to inhibit tau acetylation, and when given to transgenic mouse models of FTD, resulted in lowered levels of total tau, preserved hippocampal atrophy and improved memory de fi cits (Min et al. 2015).”
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · cited 1×
“Active immunization in transgenic mouse models with human tau pathology have been shown to have reduced tau pathology and improved performance on sensorimotor testing (Asuni et al. 2007; Theunis et al. 2013).”
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. (2008) · Brain · doi:10.1093/brain/awn234 · Cited by 442
Does corticobasal degeneration exist? A clinicopathological re-evaluation
Ling, H., O'Sullivan, S. S., Holton, J. L., Revesz, T., Massey, L. A., Williams, D. R., Paviour, D. C., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq123 · Cited by 394
18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330 · cited 1×
“18 F THK5351 is one ligand that has been shown to bind to expected tau pathology distribution in AD patients and to tau deposits in postmortem AD tissue (Harada et al. 2016 ).”
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Tolosa, E., Litvan, I., Höglinger, G. U., Burn, D., Lees, A., Andrés, M. V., Gómez‐Carrillo, B., León, T., del Ser, T., & for the TAUROS Investigators (2014) · Movement Disorders · doi:10.1002/mds.25824 · Cited by 320
Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · cited 1×
“…tau epitopes in tau transgenic mouse models resulted in reduction in tau pathology, with three studies reporting cognitive or functional improvement (Boutajangout et al. 2011; Chai et al. 2011; d ’ Abramo et al. 2013; Yanamandra et al. 2013; Castillo-Carranza et al. 2014a,b; Collin et al. 2014).”
Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294 · cited 2×
“Large clinical trials with previously hopeful disease-modifying agents have been recently completed for PSP, and although not successful, provided invaluable experience and evidence that large, multicenter international FTD clinical trials are feasible (Boxer et al. 2014).”
Self-citationCastillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278
Wischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269 · cited 1×
“LMTx has recently published phase II clinical trial results in AD, showing improvements in cognition in the middle dose but not the highest dose cohort, where it was argued the drug suffered from impaired absorption (Wischik et al. 2015).”
Preliminary Findings: Behavioral Worsening on Donepezil in Patients With Frontotemporal Dementia
Mendez, M. F., Shapira, J. S., McMurtray, A., & Licht, E. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000231744.69631.33 · Cited by 267 · cited 1×
“Discontinuation of donepezil resulted in abatement of behavioral symptoms, which was replicated in other recent studies (Mendez et al. 2007; Arciniegas and Anderson 2013; Kimura and Takamatsu 2013).”
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · cited 1×
“Active immunization in transgenic mouse models with human tau pathology have been shown to have reduced tau pathology and improved performance on sensorimotor testing (Asuni et al. 2007; Theunis et al. 2013).”
Scherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., Kramer, J. H., Rabinovici, G., Ahlijanian, M., Miller, B. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24052 · Cited by 249
Self-citationMackenzie, I. R. A., Frick, P., Grässer, F. A., Gendron, T. F., Petrucelli, L., Cashman, N. R., Edbauer, D., Kremmer, E., Prudlo, J., Troost, D., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1476-2 · Cited by 231 · cited 1×
“Although recent studies have shown that speci fi c dipeptide products are toxic in animal and cell models via cytoplasmic aggregates or nuclear inclusions and nucleolar stress, whether it is a major or exclusive pathogenic mechanism in humans remain to be elucidated (Mackenzie et al. 2015).”
Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70320-4 · Cited by 228 · cited 2×
“A number of cognitive, behavior, and motor scales have been studied and validated in longitudinal studies of FTLD syndromes (Boxer et al. 2013b).”
Self-citationGalantamine in Frontotemporal Dementia and Primary Progressive Aphasia
Kertesz, A., Morlog, D., Light, M., Blair, M., Davidson, W., Jesso, S., & Brashear, R. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000113034 · Cited by 217 · cited 13×
“Recent advancements in understanding the molecular and genetic basis of FTD, especially FTLD-tau have reached suf fi cient maturity for new drug targets to be identi fi ed, and several clinical trials based on these insights are underway.”
InfluentialPrion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target
Holmes, B. B., & Diamond, M. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.549295 · Cited by 202 · cited 1×
“Over the past years, accumulating evidence has pointed to intercellular spread of tau aggregates and its ability to propagate further aggregation via conformational change in a prion like manner (Holmes and Diamond 2014).”
TDP-43 frontotemporal lobar degeneration and autoimmune disease
Miller, Z. A., Rankin, K. P., Graff-Radford, N. R., Takada, L. T., Sturm, V. E., Cleveland, C. M., Criswell, L. A., Jaeger, P. A., Stan, T., Heggeli, K. A., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304644 · Cited by 170 · cited 1×
“In addition, it has been demonstrated that patients with GRN mutation often have co-existing autoimmune disorders (Miller et al. 2013a).”
Self-citationHöglinger, G. U., Huppertz, H., Wagenpfeil, S., Andrés, M. V., Belloch, V., León, T., del Ser, T., & for the TAUROS MRI Investigators (2014) · Movement Disorders · doi:10.1002/mds.25815 · Cited by 161
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147 · cited 2×
“The ability to detect b-amyloid pathology has led to an understanding of the limitations of a clinical diagnosis of dementia, as up to 16% of recruited patients in a previous AD trial did not have amyloid pathology by PET scan (Vellas et al. 2013).”
Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity
d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062402 · Cited by 144 · cited 1×
“…tau epitopes in tau transgenic mouse models resulted in reduction in tau pathology, with three studies reporting cognitive or functional improvement (Boutajangout et al. 2011; Chai et al. 2011; d ’ Abramo et al. 2013; Yanamandra et al. 2013; Castillo-Carranza et al. 2014a,b; Collin et al. 2014).”
Tau and Axonopathy in Neurodegenerative Disorders
Higuchi, M., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:131 · Cited by 134
Sjogren, M. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.019422 · Cited by 125 · cited 1×
“Elevated TNF-alpha levels have been demonstrated in FTD, but without clear differentiation as to which pathological subtype (Sj € ogren et al. 2004).”
Reduced CSF p-Tau 181 to Tau ratio is a biomarker for FTLD-TDP
Hu, W. T., Watts, K., Grossman, M., Glass, J., Lah, J. J., Hales, C., Shelnutt, M., Van Deerlin, V., Trojanowski, J. Q., & Levey, A. I. (2013) · Neurology · doi:10.1212/01.wnl.0000436625.63650.27 · Cited by 113
Treatment of Primary Progressive Aphasia
Tippett, D. C., Hillis, A. E., & Tsapkini, K. (2015) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0362-5 · Cited by 107 · cited 1×
“(Kortte and Rogalski 2013; Tippett et al. 2015).”
Kortte, K. B., & Rogalski, E. J. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2012.751017 · Cited by 89
Takahashi, M., Weidenheim, K. M., Dickson, D. W., & Ksiezak-Reding, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.1.33 · Cited by 56 · cited 9×
“Furthermore, the FTD-related disorders PSP and CBD are de fi ned by atypical parkinsonism, typically with substantial rigidity and infrequent tremors.”
Influential
Research works printed but not linked: 76
- 10.1007/s10072-014-1683-y · DOI
- 10.1021/bi00158a027 · DOI · Paper page
- 10.1016/j.neurobiolaging.2015.06.008 · DOI
- 10.1176/appi.neuropsych.12060158 · doi:10.1176/appi.neuropsych.12060158
- 10.1016/j.neuron.2013.02.004 · DOI · Paper page
- 10.1016/S0140-6736(15)00461-4 · DOI · Paper page
- 10.1002/mds.10211 · DOI
- 10.1097/WAD.0b013e318197852f · DOI · Paper page
- 10.1136/jnnp.2009.204081 · DOI · Paper page
- 10.1016/j.jalz.2012.03.003 · DOI · Paper page
- Brunden K. R., 2013, Microtubule‐stabilizing agents as potential therapeutics for neurodegenerative disease, Bioorg. Med. Chem., 5, 5040
- 10.1111/j.1750-3639.1999.tb00550.x · DOI · Paper page
- 10.1523/JNEUROSCI.5757-10.2011 · DOI · Paper page
- 10.3233/JAD-132477 · DOI · Paper page
- 10.1074/jbc.M110.193433 · DOI · Paper page
- 10.1074/jbc.M111.229633 · DOI · Paper page
- 10.1016/j.jagp.2013.01.060 · DOI · Paper page
- 10.1177/153331750201700504 · DOI · Paper page
- 10.1073/pnas.1301175110 · DOI · Paper page
- 10.1093/brain/awu213 · DOI · Paper page
- 10.1097/WNN.0b013e31816bdf73 · DOI · Paper page
- 10.1097/00004714-200006000-00018 · DOI · Paper page
- Dani M., 2015, Tau imaging in neurodegenerative diseases, Eur. J. Nucl. Med. Mol. Imaging, 16, 1139
- 10.1007/s00213-003-1686-5 · DOI · Paper page
- 10.1091/mbc.3.10.1141 · DOI · Paper page
- 10.1016/j.brainres.2012.02.030 · DOI · Paper page
- 10.1034/j.1600-0404.2001.103002123.x · DOI · Paper page
- 10.1097/00005072-199601000-00006 · DOI · Paper page
- 10.1080/15622970601016538 · DOI · Paper page
- 10.1093/brain/awn352 · DOI · Paper page
- 10.1212/WNL.0000000000001133 · DOI · Paper page
- 10.1002/ana.20365 · DOI · Paper page
- 10.1111/nan.12213 · DOI · Paper page
- 10.1212/01.wnl.0000325058.10218.fc · DOI · Paper page
- 10.1093/brain/awm032 · DOI · Paper page
- 10.1159/000439521 · DOI
- 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
- 10.1097/JGP.0b013e31823033f3 · DOI
- 10.4088/JCP.v69n1219a · DOI · Paper page
- Kaye E. D., 2010, Frontotemporal dementia and pharmacologic interventions, J. Neuropsychiatry Clin. Neurosci., 22, 19, 10.1176/jnp.2010.22.1.19 · DOI
- 10.1111/j.1447-0594.2012.00956.x · DOI
- 10.1159/000114065 · doi:10.1159/000114065
- 10.1007/s00415-015-7657-z · DOI
- 10.1001/archneur.55.8.1099 · doi:10.1001/archneur.55.8.1099
- 10.1073/pnas.1318835110 · DOI · Paper page
- 10.1159/000077171 · DOI · Paper page
- 10.1002/ana.22424 · DOI · Paper page
- 10.1016/j.jalz.2009.04.1231 · DOI · Paper page
- 10.1212/WNL.57.3.467 · DOI · Paper page
- 10.1212/WNL.0000000000001642 · DOI · Paper page
- 10.1002/mds.20465 · DOI · Paper page
- 10.1097/WAD.0b013e31815bf774 · DOI · Paper page
- 10.1159/000067021 · DOI · Paper page
- 10.1177/153331750301800410 · DOI · Paper page
- 10.2165/00002512-200421140-00003 · DOI
- 10.1212/01.wnl.0000259519.78480.c3 · DOI · Paper page
- 10.1136/jnnp.2010.238899 · DOI
- 10.1002/gps.774 · DOI · Paper page
- 10.1097/JCP.0b013e31823f91b9 · DOI
- 10.1159/000051219 · DOI · Paper page
- 10.1136/jnnp.2009.173260 · DOI
- 10.1097/01.jcp.0000426190.64916.3b · DOI
- 10.1212/01.wnl.0000172911.39167.b6 · DOI · Paper page
- 10.1212/01.WNL.0000158425.46019.5C · DOI · Paper page
- 10.1186/alzrt149 · DOI
- 10.1111/j.1479-8301.2012.00429.x · DOI
- 10.1155/2013/547853 · DOI
- 10.1002/ana.21621 · DOI · Paper page
- 10.1097/WAD.0b013e318047df5d · DOI · Paper page
- 10.4088/JCP.v58n0506 · DOI · Paper page
- 10.1016/S1474-4422(08)70194-7 · DOI · Paper page
- 10.1001/jama.291.3.317 · DOI · Paper page
- 10.3233/JAD-2010-101632 · DOI · Paper page
- 10.1016/j.parkreldis.2011.10.013 · DOI · Paper page
- Yang Y., 2001, Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method, Acta Neuropathol., 101, 256, 10.1007/s004010000293 · DOI
- 10.1002/ana.10222 · DOI · Paper page
Cited by
Olney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
Tsoy, E., Kiekhofer, R. E., Guterman, E. L., Tee, B. L., Windon, C. C., Dorsman, K. A., Lanata, S. C., Rabinovici, G. D., Miller, B. L., Kind, A. J. H., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0399 · Cited by 182
18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O’Neil, J. P., Janabi, M., Baker, S., Lee, S. E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0470-7 · Cited by 164
Self-citationTemporal order of clinical and biomarker changes in familial frontotemporal dementia
Staffaroni, A. M., Quintana, M., Wendelberger, B., Heuer, H. W., Russell, L. L., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Petrucelli, L., Gendron, T. F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01942-9 · Cited by 140
Self-citationProgranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
“Of several recent or ongoing trials for potential FTD disease-modifying drugs listed in ClinicalTrails.gov (Tsai and Boxer, 2016) only two are targeted towards increasing brain progranulin levels or secretion, namely a phase 2 trial with the histone deacetylase (HDAC) inhibitor FRM-0334…”
BackgroundInfluential
Metadata
- Authors
- Tsai, R. M., & Boxer, A. L.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-06-15
- Volume
- 138
- Issue
- S1
- Pages
- 211-221
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2443339653
- Cited by
- 143
- References
- 43
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Institutes of Health (U54NS092089, R01AG038791)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.